MetaCap

Telix Pharmaceuticals Limited ADR (TLX)

NASDAQ: TLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

8.37-0.34 (-3.90%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TLX stock chart

Technical analysis

Key statistics

All statistics
52-week range
6.28 – 13.11
Day range
8.37 – 8.70
Volume / Avg
269.43K / 356.74K
Beta
—

52-week range

$6.28$13.11

TLX stock today

Telix Pharmaceuticals (TLX) closed at $8.37 on Nov 20, down 3.90% (-$0.34), versus the S&P 500's 3.70% decline. At this level, TLX sits in the middle of its 52-week range of $6.28 to $13.11: 36.2% below the high, set on Sep 15, 2026 and 33.3% above the low. TLX is up 11.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 6.1%.

Telix Pharmaceuticals trades at 83.7x its trailing twelve-month earnings per share of $0.10.

Summary generated from market data by MetaCap's automated system. Methodology

About Telix Pharmaceuticals

Company profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D
Headquarters
North Melbourne, VIC
Employees
1,120

Financial highlights

Full financials

In fiscal 2025, Telix Pharmaceuticals generated $803.8 million in revenue, up 55.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Telix Pharmaceuticals reported a net loss of $7.1 million, compared with net income of $33.7 million a year earlier. Gross margin was 53.1% (down from 65.1%) and operating margin 3.7%.

Telix Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$803.79M$516.55M$332.98M
Growth+55.61%+55.13%—
Net income$-7.13M$33.69M$4.21M
EPS (diluted)$-0.0211$0.0976$0.013

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$19.66+134.89%

  • Strong buy 0
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $17.20High $21.11

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

TLX news

All TLX news

Telix Pharmaceuticals peers

Health Care sector
TLX peer companies
CompanyPrice% ChgMarket capCompare
SLSSELLAS Life Sciences Group Inc.13.66-8.08%$2.78Bvs TLX
DYNDyne Therapeutics Inc.15.50-3.31%$2.90Bvs TLX
ACADACADIA Pharmaceuticals Inc.17.11-2.73%$2.96Bvs TLX
LEGNLegend Biotech Corporation ADR15.25-5.28%$2.96Bvs TLX
ZLABZai Lab Limited ADR21.03-4.06%$2.63Bvs TLX
BHCBausch Health Companies Inc.8.22-3.97%$3.08Bvs TLX
XERSXeris Biopharma Holdings Inc.16.97+2.11%$3.10Bvs TLX
VKTXViking Therapeutics Inc.24.77-4.14%$3.16Bvs TLX

Indexes, lists and sector

Telix Pharmaceuticals stock FAQ

What is Telix Pharmaceuticals's stock price today?

TLX last traded at $8.37 as of Nov 20, 4:00 PM EST, down 3.90% on the day. Prices are delayed at least 15 minutes.

What is TLX's P/E ratio?

TLX trades at a trailing P/E ratio of 83.70.

Who is Telix Pharmaceuticals's CEO?

Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D is the chief executive officer of Telix Pharmaceuticals Limited ADR, which has about 1,120 employees.

What is the TLX 52-week high?

The 52-week high for TLX is $13.11 and the 52-week low is $6.28. The stock is currently 36.2% below its high.

Compare TLX